

Supporting Information

Palladium-Catalyzed Heteroannulation of [60]Fullerene with *N*-(2-Arylethyl) Sulfonamides via C–H Bond Activation

Yi-Tan Su,^a You-Liang Wang^a and Guan-Wu Wang^{*a,b}

^a*Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Soft Matter Chemistry, and Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China; E-mail: gwang@ustc.edu.cn*

^b*State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu 730000, P. R. China*

gwang@ustc.edu.cn


Table of Contents

Experimental procedures and characterization data	S2
¹H NMR spectrum of compound 2a	S10
¹³C NMR spectrum of compound 2a	S11
¹H NMR spectrum of compound 2b	S12
¹³C NMR spectrum of compound 2b	S17
¹H NMR spectrum of compound 2c	S24
¹³C NMR spectrum of compound 2c	S25
¹H NMR spectrum of compound 2d	S31
¹³C NMR spectrum of compound 2d	S32
¹H NMR spectrum of compound 2e	S38
¹³C NMR spectrum of compound 2e	S39
¹H NMR spectrum of compound 2f	S45
¹³C NMR spectrum of compound 2f	S46
¹H NMR spectrum of compound 2g	S52
¹³C NMR spectrum of compound 2g	S53
¹H NMR spectrum of compound 2h	S59
¹³C NMR spectrum of compound 2h	S60
¹H NMR spectrum of compound 2i	S66
¹³C NMR spectrum of compound 2i	S67
¹H NMR spectrum of compounds 3a and 4a	S73
¹H NMR spectrum of compounds 3i and 4i	S76
¹³C NMR spectrum of compound 3i	S79
Voltammograms and data of compounds 2a-i, 5 and C₆₀	S83


Experimental procedures and characterization data.

General procedure for the preparation of C₆₀-fused tetrahydrobenzazepines


2a-2i: To a 15 mL sealed tube containing C₆₀ (36 mg, 0.050 mol), *N*-(2-arylethyl) sulfonamide derivative **1a** (**1b-1i**, 0.15 mmol), Cu(OAc)₂ (27.2 mg, 0.15 mmol) and Pd(OAc)₂ (2.2 mg, 0.010 mmol) were added ODCB (6 mL) and TFA (0.2 mL). After being stirred at 80 °C for 10 h (6 h for **1f**), the reaction mixture was filtered through a silica gel plug to remove any insoluble material. After evaporation in vacuo, the residue was separated on a silica gel column with carbon disulfide as the eluent to give unreacted C₆₀, and subsequent elution with carbon disulfide/dichloromethane provided **2a** (**2b-2i**).



C₆₀-fused tetrahydrobenzazepine 2a: According to the general procedure, the reaction of C₆₀ (35.9 mg, 0.05 mmol) with **1a** (41.0 mg, 0.15 mmol) afforded first recovered C₆₀ (16.5 mg, 46%) and then **2a** (15.8 mg, 32%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.28 (d, 8.0 Hz, 1H), 7.60-7.53 (m, 5H), 7.09 (d, *J* = 8.4 Hz, 2H), 5.33-5.23 (m, 1H), 5.15-5.06 (m, 1H), 4.63 (dd, *J* = 13.6, 7.6 Hz, 1H), 3.43 (dd, *J* = 14.4, 6.8 Hz, 1H), 2.30 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 154.40, 153.83, 150.03, 149.61, 147.86, 147.27, 146.23, 146.16 (2C), 145.81, 145.76 (2C), 145.72, 145.66, 145.50, 145.34 (2C), 145.31, 145.23, 145.11, 145.00, 144.95 (3C), 144.79, 144.71, 144.49, 144.45, 144.31, 144.20, 144.08, 143.93, 142.80, 142.64, 142.52, 142.34 (2C), 142.15 (2C), 142.00, 141.90, 141.85, 141.83, 141.77, 141.70, 141.35 (2C), 141.15, 141.07, 140.91, 140.85, 139.91, 139.83, 139.67, 139.40, 139.10, 139.01, 137.77, 137.70, 137.27 (aryl C), 136.03, 133.82, 130.81 (aryl C), 129.56 (aryl C), 128.93 (aryl C), 128.81 (2C, aryl C), 128.09 (aryl C), 126.25 (2C, aryl C), 78.60 (sp³-C of C₆₀), 71.68 (sp³-C of C₆₀), 50.00 (CH₂), 33.60 (CH₂), 21.24 (CH₃); FT-IR ν/cm⁻¹ (KBr) 2915, 1456, 1431, 1344, 1155, 1117, 1091, 1048, 990, 744, 670, 562, 525; UV-vis (CHCl₃) λ_{max}/nm (log ε) 259 (4.99), 322 (4.53), 435 (3.41), 694 (2.43); (-)ESI-MS *m/z* calcd for C₇₅H₁₅NO₂S [M] 993.0829, found 993.0839.




C₆₀-fused tetrahydrobenzazepine 2b: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1b** (46.5 mg, 0.15 mmol) afforded first recovered C₆₀ (13.5 mg, 38%) and then **2b** (12.5 mg, 24%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.28 (d, *J* = 2.0 Hz, 1H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.58 (d, *J* = 8.0, 2.0 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 2H), 5.30-5.21 (m, 1H), 5.17-5.08 (m, 1H), 4.65 (dd, *J* = 13.4, 7.4 Hz, 1H), 3.43 (dd, *J* = 14.6, 7.0 Hz, 1H), 2.31 (s, 3H); ¹³C NMR [75 MHz, CS₂/ODCB-*d*₄ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 153.82, 152.92, 150.23, 149.56, 148.07, 147.53, 146.43, 146.39, 146.37, 146.04, 145.99 (4C), 145.90, 145.72, 145.68, 145.45, 145.43, 145.32, 145.23, 145.20 (2C), 145.13, 145.10, 144.80, 144.56, 144.46, 144.38 (2C), 144.29, 144.18, 142.97, 142.84, 142.80, 142.72, 142.56 (2C), 142.48, 142.40, 142.29, 142.18, 142.13, 142.07, 141.95, 141.77, 141.53, 141.39, 141.21, 141.14, 141.11, 140.15, 139.98, 139.92, 139.79, 139.30, 139.15, 138.18, 137.75 (aryl C), 136.55 (aryl C), 136.48, 134.42 (aryl C), 134.08, 129.23 (2C, aryl C), 129.00 (aryl C), 126.60 (2C, aryl C), 79.01 (sp³-C of C₆₀), 71.64 (sp³-C of C₆₀), 50.12 (CH₂), 33.31 (CH₂), 21.36 (CH₃) (Note: 2C of the phenyl ring were overlapped by very strong signals of the bulk ODCB-*d*₄); FT-IR ν/cm⁻¹ (KBr) 2920, 1455, 1344, 1263, 1157, 1092, 1067, 1024, 811, 670, 561, 527; UV-vis (CHCl₃) λ_{max}/nm (log ε) 258 (4.99), 321 (4.47), 435 (3.43), 693 (2.44); (-)ESI-MS *m/z* calcd for C₇₅H₁₄³⁵ClNO₂S [M⁻] 1027.0439, found 1027.0432.




C₆₀-fused tetrahydrobenzazepine 2c: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1c** (53.1 mg, 0.15 mmol) afforded first recovered C₆₀ (23.3 mg, 65%) and then **2c** (6.4 mg, 12%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.36 (d, *J* = 2.0 Hz, 1H), 7.69 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.58 (d, *J* = 8.2 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.08 (d, *J* = 8.2 Hz, 2H), 5.26-5.16 (m, 1H), 5.13-5.04 (m, 1H), 4.61 (dd, *J* = 13.2, 7.2 Hz, 1H), 3.40 (dd, *J* = 14.4, 6.8 Hz, 1H), 2.31 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 153.60, 152.66, 149.75, 149.25, 147.89, 147.31, 146.25, 146.21 (2C), 145.86, 145.82, 145.80, 145.77, 145.69,


145.52, 145.36, 145.29, 145.26, 145.13, 145.11, 145.07 (2C), 144.98, 144.93, 144.90, 144.69, 144.41, 144.26, 144.21, 144.18, 143.94, 143.92, 142.82, 142.66, 142.65, 142.55, 142.38 (2C), 142.21, 142.16, 142.09, 142.01, 141.90, 141.86, 141.73, 141.69, 141.38, 141.26, 140.95, 140.85, 140.61, 139.91, 139.85, 139.64, 139.47, 139.17, 138.94, 137.87, 137.51, 136.27, 136.24, 134.01, 132.38 (aryl C), 132.25 (aryl C), 131.62 (aryl C), 128.88 (2C, aryl C), 126.31 (2C, aryl C), 122.32 (aryl C), 78.59 (sp³-C of C₆₀), 71.16 (sp³-C of C₆₀), 49.73 (CH₂), 33.08 (CH₂), 21.28 (CH₃); FT-IR ν/cm^{-1} (KBr) 2922, 1463, 1345, 1266, 1157, 1089, 1067, 990, 809, 670, 562, 527; UV-vis (CHCl₃) $\lambda_{\text{max}}/\text{nm}$ (log ϵ) 258 (4.99), 323 (4.48), 435 (3.42), 693 (2.45); (-)ESI-MS m/z calcd for C₇₅H₁₄⁷⁹BrNO₂S [M⁻] 1070.9934, found 1070.9933.



C₆₀-fused tetrahydrobenzazepine 2d: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1d** (43.5 mg, 0.15 mmol) afforded first recovered C₆₀ (13.7 mg, 38%) and then **2d** (20.2 mg, 40%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.11 (s, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 5.29-5.20 (m, 1H), 5.17-5.09 (m, 1H), 4.65 (dd, J = 13.2, 7.2 Hz, 1H), 3.43 (dd, J = 14.2, 6.6 Hz, 1H), 2.52 (s, 3H), 2.30 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 154.69, 154.06, 150.20, 149.82, 148.00, 147.41, 146.35, 146.28 (2C), 145.94, 145.89 (2C), 145.85, 145.79, 145.60 (2C), 145.49, 145.45, 145.36, 145.25, 145.11 (2C), 145.08, 145.05, 144.86, 144.83, 144.64, 144.60, 144.40, 144.33, 144.24, 144.06, 142.93, 142.77, 142.65, 142.47 (2C), 142.28 (2C), 142.12, 142.10, 142.03, 141.98, 141.97, 141.82, 141.48, 141.33, 141.25 (2C), 140.99 (2C), 140.02, 139.96, 139.80, 139.50, 139.18, 139.14, 137.88 (2C), 137.68 (aryl C), 136.08, 134.38 (aryl C), 133.87, 130.84 (aryl C), 130.32 (aryl C), 129.64 (aryl C), 128.96 (2C, aryl C), 126.35 (2C, aryl C), 78.77 (sp³-C of C₆₀), 71.80 (sp³-C of C₆₀), 50.15 (CH₂), 33.20 (CH₂), 21.45 (CH₃), 21.29 (CH₃); FT-IR ν/cm^{-1} (KBr) 2919, 1450, 1330, 1156, 1090, 1070, 986, 810, 669, 525; UV-vis (CHCl₃) $\lambda_{\text{max}}/\text{nm}$ (log ϵ) 258 (5.00), 322 (4.41), 435 (3.36), 693 (2.38); (-)ESI-MS m/z calcd for C₇₆H₁₇NO₂S [M⁻] 1007.0985, found 1007.0992.




C₆₀-fused tetrahydrobenzazepine 2e: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1e** (43.4 mg, 0.15 mmol) afforded first recovered C₆₀ (14.0 mg, 39%) and then **2e** (18.8 mg, 37%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.20 (d, *J* = 8.0 Hz, 1H), 7.64 (d, *J* = 8.2 Hz, 2H), 7.44 (d, *J* = 1.6 Hz, 1H), 7.37 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.10 (d, *J* = 8.2 Hz, 2H), 5.31-5.22 (m, 1H), 5.19-5.11 (m, 1H), 4.67 (dd, *J* = 13.0, 7.0 Hz, 1H), 3.41 (dd, *J* = 14.2, 6.6 Hz, 1H), 2.55 (s, 3H), 2.29 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 155.10, 154.40, 150.29, 150.10, 148.29, 147.69, 146.61, 146.54, 146.53, 146.20, 146.15 (2C), 146.10, 146.06, 145.84, 145.81, 145.76, 145.70, 145.63, 145.53, 145.39, 145.37, 145.35, 145.27, 145.07, 145.06, 144.87 (2C), 144.62, 144.60, 144.54, 144.33, 143.17, 143.02, 142.89, 142.72 (2C), 142.53 (4C), 142.36, 142.28 (2C), 142.21, 142.09, 141.72, 141.50 (2C), 141.21, 141.13, 140.30, 140.26, 140.10, 139.72 (aryl C), 139.48, 139.42, 139.17, 138.16, 138.09, 137.49 (aryl C), 136.31, 134.11, 131.95 (aryl C), 129.24 (2C, aryl C), 128.99 (aryl C), 128.98 (aryl C), 126.58 (2C, aryl C), 78.96 (sp³-C of C₆₀), 71.90 (sp³-C of C₆₀), 50.41 (CH₃), 33.65 (CH₂), 21.44 (CH₃), 21.23 (CH₃); FT-IR ν/cm⁻¹ (KBr) 2919, 1449, 1335, 1261, 1155, 1120, 1082, 807, 748, 668, 554, 523; UV-vis (CHCl₃) λ_{max}/nm (log ε) 258 (5.00), 321 (4.52), 435 (3.44), 693 (2.55); (-)ESI-MS *m/z* calcd for C₇₆H₁₇NO₂S [M⁻] 1007.0985, found 1007.0981.




C₆₀-fused tetrahydrobenzazepine 2f: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1f** (45.8 mg, 0.15 mmol) afforded first recovered C₆₀ (26.8 mg, 74%) and then **2f** (10.0 mg, 20%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 7.90 (d, *J* = 2.4 Hz, 1H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.55 (d, *J* = 8.0 Hz, 1H), 7.15 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 2H), 5.26-5.09 (m, 2H), 4.71-4.59 (m, 1H), 3.91 (s, 3H), 3.49-3.37 (m, 1H), 2.30 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 159.66 (aryl C), 154.71, 153.95, 150.41, 149.98, 148.29, 147.71, 146.62, 146.54 (2C), 146.21, 146.17 (2C), 146.12, 146.05, 145.84, 145.82, 145.75, 145.71, 145.63, 145.52, 145.40, 145.36 (2C), 145.30, 145.12, 145.07, 144.86,

144.84, 144.61, 144.59, 144.48, 144.35, 143.16, 143.12, 143.02 (2C), 142.88, 142.72 (2C), 142.55 (2C), 142.36, 142.28, 142.21 (2C), 142.10, 141.71, 141.51, 141.48, 141.19, 141.09, 140.32, 140.21, 140.08, 139.75, 139.41, 139.34, 138.16, 138.11, 136.37, 134.22, 131.88 (aryl C), 129.94 (aryl C), 129.25 (2C, aryl C), 126.60 (2C, aryl C), 116.90 (aryl C), 113.37 (aryl C), 79.05 (sp³-C of C₆₀), 71.99 (sp³-C of C₆₀), 55.41 (CH₃O), 50.48 (CH₂), 32.78 (CH₂), 21.44 (CH₃); FT-IR ν/cm^{-1} (KBr) 2921, 1456, 1434, 1342, 1260, 1154, 1111, 1090, 1046, 807, 669, 560, 525; UV-vis (CHCl₃) $\lambda_{\text{max}}/\text{nm}$ (log ϵ) 258 (4.98), 323 (4.48), 435 (3.33), 693 (2.46); (-)ESI-MS m/z calcd for C₇₆H₁₇NO₃S [M⁻] 1023.0935, found 1023.0938.




C₆₀-fused tetrahydrobenzazepine 2g: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1g** (45.5 mg, 0.15 mmol) for 6 h afforded first recovered C₆₀ (8.9 mg, 25%) and then **2g** (24.1 mg, 47%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.03 (s, 1H), 7.64 (d, J = 8.4 Hz, 2H), 7.38 (s, 1H), 7.09 (d, J = 8.4 Hz, 2H), 5.25-5.10 (m, 2H), 4.70-4.61 (m, 1H), 3.44-3.34 (m, 1H), 2.45 (s, 3H), 2.41 (s, 3H), 2.29 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 155.21, 154.44, 150.33, 150.14, 148.21, 147.61, 146.55, 146.49, 146.47, 146.14, 146.09 (2C), 146.03, 145.99, 145.90, 145.78, 145.71, 145.67, 145.56, 145.47, 145.33, 145.31, 145.28, 145.22, 145.02, 144.97, 144.83, 144.82, 144.58, 144.54, 144.50, 144.26, 143.12, 142.95, 142.83, 142.65 (2C), 142.47 (2C), 142.35, 142.31, 142.27, 142.22, 142.16, 142.00, 141.67, 141.49, 141.45, 141.20, 141.16, 140.21 (2C), 140.04, 139.64, 139.40, 139.34, 139.12, 138.16, 138.11, 138.02, 136.39 (aryl C), 136.23, 134.75 (aryl C), 133.86, 132.43 (aryl C), 130.16 (aryl C), 129.14 (2C, aryl C), 126.55 (2C, aryl C), 78.84 (sp³-C of C₆₀), 71.77 (sp³-C of C₆₀), 50.33 (CH₂), 33.23 (CH₂), 21.42 (CH₃), 19.85 (CH₃), 19.53 (CH₃); FT-IR ν/cm^{-1} (KBr) 2915, 1447, 1432, 1341, 1262, 1154, 1089, 982, 808, 728, 669, 562, 525; UV-vis (CHCl₃) $\lambda_{\text{max}}/\text{nm}$ (log ϵ) 259 (4.99), 322 (4.49), 437 (3.45), 695 (2.45); (-)ESI-MS m/z calcd for C₇₇H₁₉NO₂S [M⁻] 1021.1142, found 1021.1148.



2h


C₆₀-fused tetrahydrobenzazepine 2h: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1h** (30.1 mg, 0.15 mmol) afforded first recovered C₆₀ (12.3 mg, 34%) and then **2h** (17.1 mg, 37%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.28 (d, *J* = 7.8 Hz, 1H), 7.64-7.51 (m, 3H), 5.32-5.22 (m, 1H), 4.90-4.81 (m, 1H), 4.59 (dd, *J* = 14.0, 7.6 Hz, 1H), 3.39 (dd, *J* = 14.8, 7.2 Hz, 1H), 3.09 (s, 3H); ¹³C NMR [75 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 154.33, 154.23, 150.23, 149.89, 148.35, 147.79, 146.68, 146.63, 146.57, 146.29, 146.19 (3C), 146.16, 146.05, 145.72 (2C), 145.69, 145.57, 145.55, 145.48, 145.42, 145.38, 145.28, 145.20, 145.17, 144.92 (2C), 144.76, 144.67, 144.42, 144.21, 143.25, 143.15, 143.02, 142.95, 142.83, 142.79, 142.69, 142.60, 142.45, 142.34 (2C), 142.19, 142.15, 141.92, 141.69, 141.55, 141.54, 140.75, 140.27, 140.21, 139.93, 139.90, 139.41, 139.18, 138.16, 137.77 (aryl C), 136.38, 134.19, 131.33 (aryl C), 129.94 (aryl C), 129.11 (aryl C), 128.35 (aryl C), 79.50 (sp³-C of C₆₀), 71.85 (sp³-C of C₆₀), 49.75 (CH₂), 44.90 (CH₃), 33.45 (CH₂); FT-IR ν/cm⁻¹ (KBr) 2924, 1454, 1431, 1338, 1262, 1148, 1117, 1071, 1046, 951, 748, 551, 521; UV-vis (CHCl₃) λ_{max}/nm (log ε) 257 (4.99), 320 (4.50), 434 (3.42), 693 (2.50); (-)ESI-MS *m/z* calcd for C₆₉H₁₁NO₂S [M⁻] 917.0516, found 917.0515.




2i

C₆₀-fused tetrahydrobenzazepine 2i: According to the general procedure, the reaction of C₆₀ (36.0 mg, 0.05 mmol) with **1i** (52.1 mg, 0.15 mmol) afforded first recovered C₆₀ (23.5 mg, 65%) and then **2i** (12.8 mg, 24%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.26 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.60-7.49 (m, 3H), 7.04 (d, *J* = 8.4 Hz, 2H), 6.03 (dd, *J* = 12.0, 6.8 Hz, 1H), 5.43 (dd, *J* = 15.0, 12.0 Hz, 1H), 4.21 (dq, *J* = 10.8, 7.2 Hz, 1H), 3.95 (dq, *J* = 10.8, 7.2 Hz, 1H), 3.86 (dd, *J* = 15.0, 6.8 Hz, 1H), 2.30 (s, 3H), 1.16 (t, 7.2 Hz, 3H); ¹³C NMR [100 MHz, CS₂/CDCl₃ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 170.73 (C=O), 154.93, 153.88, 149.94, 147.91, 147.68, 147.25, 146.32, 146.26, 146.15, 145.90, 145.81, 145.79, 145.76 (2C), 145.58, 145.54, 145.51, 145.40 (2C), 145.31, 145.14, 145.07, 145.00, 144.93 (2C), 144.77, 144.67, 144.46, 144.39, 144.21, 144.03, 143.89, 142.78, 142.62, 142.58, 142.41, 142.38, 142.27, 142.23, 142.12, 142.05, 142.03, 142.01, 141.78, 141.72, 141.62, 141.44, 141.28,

141.18, 141.07, 140.03, 139.58, 139.56, 139.13, 139.06, 139.03, 138.35, 138.27, 138.05, 137.01 (aryl C), 135.84, 133.30, 130.60 (aryl C), 129.39 (aryl C), 129.23 (aryl C), 128.39 (aryl C), 128.36 (2C, aryl C), 128.20 (2C, aryl C), 78.89 (sp³-C of C₆₀), 71.07 (sp³-C of C₆₀), 62.45 (CH₂), 61.57 (CH₂), 35.09 (CH₂), 21.27 (CH₃), 14.02 (CH₃); FT-IR ν/cm^{-1} (KBr) 2926, 1727, 1449, 1330, 1232, 1153, 1088, 1020, 812, 748, 557, 525; UV-vis (CHCl₃) $\lambda_{\text{max}}/\text{nm}$ (log ϵ) 258 (5.00), 321 (4.53), 433 (3.36), 690 (2.52); (-)ESI-MS m/z calcd for C₇₈H₁₉NO₄S [M^-] 1065.1040, found 1065.1046. $[\alpha]_{\text{D}}^{25\text{ }^\circ\text{C}} = +5.82$ (CHCl₃).




Transformation of 2a to fullerotetrahydronaphthalene 3a and fulleroindane 4a: A mixture of **2a** (19.9 mg, 0.02 mmol) and TfOH (18.0 μL , 0.20 mmol) in ODCB (6 mL) was stirred at 25 $^\circ\text{C}$ for 45 min. After evaporation in vacuo, the residue was separated on a silica gel column with carbon disulfide/dichloromethane as the eluent to give unreacted **2a** (2.0 mg, 10%) and rearrangement products fullerotetrahydronaphthalene **3a** and fulleroindane **4a** (16.3 mg, 82%) as an amorphous black solid: mp $>300\text{ }^\circ\text{C}$; ¹H NMR (400 MHz, CS₂/CDCl₃) δ 8.43-8.38 (m, 0.80 \times 1H, **3a**), 8.36-8.33 (m, 0.20 \times 1H, **4a**), 7.65 (d, $J = 8.2$ Hz, 0.80 \times 2H, **3a**), 7.63 (d, $J = 8.4$ Hz, 0.20 \times 2H, **4a**), 7.54-7.42 (m, 3H, **3a** + **4a**), 7.12 (d, $J = 8.2$ Hz, 2H, **3a** + **4a**), 5.46 (ddd, $J = 10.2, 4.0, 2.0$ Hz, 0.80 \times 1H, **3a**), 5.29 (d, $J = 11.2$ Hz, 0.20 \times 1H, **4a**), 5.25 (d, $J = 10.2$ Hz, 0.80 \times 1H, **3a**), 5.07-5.01 (m, 0.20 \times 1H, **4a**), 4.47 (d, $J = 15.2$ Hz, 0.80 \times 1H, **3a**), 4.19-4.12 (m, 0.20 \times 1H, **4a**), 3.52-3.47 (m, 0.20 \times 1H, **4a**), 3.49 (dd, $J = 15.2, 4.0$ Hz, 0.80 \times 1H, **3a**), 2.36 (s, 0.20 \times 3H, **4a**), 2.35 (s, 0.80 \times 3H, **3a**); (-)ESI-MS m/z calcd for C₇₅H₁₅NO₂S [M^-] 993.0829, found 993.0821.



Transformation of 2i to fullerotetrahydronaphthalene 3i and fulleroindane 4i: A mixture of **2i** (21.3 mg, 0.02 mmol) and TfOH (18.0 μL , 0.20 mmol) in ODCB (6 mL) was stirred at 25 $^\circ\text{C}$ for 2 h. After evaporation in vacuo, the residue was separated on a silica gel column with carbon disulfide/dichloromethane as the eluent


to give unreacted **2i** (7.9 mg, 37%) and rearrangement products fullerotetrahydronaphthalene **3i** and fulleroindane **4i** (11.5 mg, 55%) as an amorphous black solid: mp >300 °C; ¹H NMR (400 MHz, CS₂/DMSO-*d*₆) δ 9.09 (s, 0.89 × 1H, **3i**), 8.22 (d, *J* = 8.0 Hz, 0.89 × 1H, **3i**), 8.16 (d, *J* = 7.2 Hz, 0.11 × 1H, **4i**), 7.78 (d, *J* = 8.4 Hz, 0.89 × 2H, **3i**), 7.49 (d, *J* = 7.8 Hz, 0.11 × 2H, **4i**), 7.38-7.26 (m, 0.89 × 5H, **3i**), 7.17 (t, *J* = 7.8 Hz, 0.11 × 1H, **4i**), 7.05 (d, *J* = 7.8 Hz, 0.11 × 2H, **4i**), 6.96 (d, *J* = 7.8 Hz, 0.11 × 1H, **4i**), 6.85 (t, *J* = 7.4 Hz, 0.11 × 1H, **4i**), 4.74 (d, *J* = 14.8 Hz, 0.89 × 1H, **3i**), 4.69 (d, *J* = 16.4 Hz, 0.11 × 1H, **4i**), 4.17 (d, *J* = 16.4 Hz, 0.11 × 1H, **4i**), 4.09-4.02 (m, 0.11 × 2H, **4i**), 3.86 (dq, *J* = 10.8, 7.2 Hz, 0.89 × 1H, **3i**), 3.57 (d, *J* = 14.8 Hz, 1H × 0.89, **3i**), 3.51 (dq, *J* = 10.8, 7.2 Hz, 0.89 × 1H, **3i**), 2.48 (s, 0.89 × 3H, **3i**), 2.43 (s, 0.11 × 3H, **4i**), 1.12 (t, *J* = 7.2 Hz, 0.11 × 3H, **4i**), 0.74 (t, *J* = 7.2 Hz, 0.89 × 3H, **3i**); ¹³C NMR of **3i** [100 MHz, CS₂/DMSO-*d*₆ with Cr(acac)₃ as relaxation reagent] (all 1C unless indicated) δ 166.99 (C=O), 159.55, 153.27, 152.45, 151.86, 148.35, 147.10, 146.55, 146.38, 146.30, 145.27 (2C), 145.17, 145.11, 145.10, 144.93, 144.80, 144.73, 144.70, 144.67, 144.31, 144.03 (2C), 143.97 (2C), 143.92, 143.86, 143.81, 143.67, 143.46, 143.42, 143.35, 142.48, 141.86, 141.73, 141.47 (2C), 141.33 (2C), 141.19, 141.17, 141.09, 140.92, 140.87, 140.80, 140.53, 140.39, 140.23, 140.20 (2C), 140.04, 139.88, 139.75, 138.91, 137.47, 137.29, 137.26, 137.10, 137.02, 136.70, 135.72, 133.98, 130.60 (aryl C), 129.17 (aryl C), 127.83 (2C, aryl C), 127.49 (aryl C), 126.10 (aryl C), 125.85 (aryl C), 125.32 (2C, aryl C), 71.95 (sp³-C of C₆₀), 69.06 (sp³-C of C₆₀), 67.52, 60.22 (OCH₂), 38.65 (CH₂), 20.64 (CH₃), 12.54 (CH₃); FT-IR ν/cm⁻¹ (KBr) 2922, 1740, 1433, 1329, 1245, 1187, 1159, 1092, 1047, 811, 743, 662, 551, 527; UV-vis (CHCl₃) λ_{max}/nm (log ε) 258 (5.00), 318 (4.59), 435 (3.42), 693 (2.42); (-)ESI-MS *m/z* calcd for C₇₈H₁₉NO₄S [*M*⁻] 1065.1040, found 1065.1036.

¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound **2a**




```


NAME          svtL 140505-01
EXPNO         10
PROCNO        1
Date_         20140506
Time          11.31
INSTRUM       spect
PROBHD        5 mm PABBO BB7
PULPROG       zg30
TD            65536
SOLVENT       CDCl3
NS            32
SFRH          8012.826 Hz
FIDRES        0.122266 Hz
AQ            4.0894966 sec
RG            152.87
DM            62.400 usec
DE            6.50 usec
DI            20002 K
D1            1.00000000 sec
TD0           1
=====
CHANNEL f1
SFO1          400.1324710 MHz
NUC1          1H
SI            10.0 usec
SF            400.1300247 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
  
```




¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound 2a




The detailed ^{13}C NMR spectrum of compound **2a** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2a** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2a** (143–140 ppm)




The detailed ^{13}C NMR spectrum of compound **2a** (147–143 ppm)




The detailed ^{13}C NMR spectrum of compound **2a** (155–147 ppm)




¹³C NMR (75 M, CS₂/ODCB-*d*₄) spectrum of compound **2b**






The detailed ^{13}C NMR spectrum of compound **2b** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2b** (141–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2b** (144–141 ppm)




The detailed ^{13}C NMR spectrum of compound **2b** (149–144 ppm)




The detailed ^{13}C NMR spectrum of compound **2b** (155–150 ppm)



¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound **2c**



¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound 2c




```

NAME          syt140509
EXPNO         13
PROCNO        1
Date_         20140511
Time          18:00
INSTRUM       spect
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS           34153
DS           4
SWH           17985.611 Hz
FIDRES        0.274439 Hz
AQ           1.8219508 sec
RG           9195.2
DW           27.800 usec
DE           6.50 usec
TE           300.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0          1


===== CHANNEL f1 =====
NUC1          13C
P1           13.00 usec
PL1          -1.00 dB
SFO1         75.4768051 MHz

===== CHANNEL f2 =====
CPDPRG2      wa1tz16
NUC2          1H
P2           80.00 usec
PL2          2.00 dB
PL12         18.48 dB
PL13         18.48 dB
SFO2         300.1312005 MHz
SI           32768
SF           75.4677896 MHz
WDW          EM
SSB          0
LB           0.50 Hz
GB           0
PC           0.50
  
```


The detailed ^{13}C NMR spectrum of compound **2c** (135–121 ppm)




The detailed ^{13}C NMR spectrum of compound **2c** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2c** (143–140 ppm)




The detailed ^{13}C NMR spectrum of compound **2c** (147–143 ppm)




The detailed ^{13}C NMR spectrum of compound **2c** (155–147 ppm)




¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound 2d




¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound 2d




The detailed ^{13}C NMR spectrum of compound **2d** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2d** (141–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2d** (143–140 ppm)




The detailed ^{13}C NMR spectrum of compound **2d** (147–143 ppm)



The detailed ^{13}C NMR spectrum of compound **2d** (157–147 ppm)




¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound **2e**




```

NAME          syc111230-2-15
PROCNO       1
Date_        20120103
Time         8.04
PROBHD       5 mm PABBO
PULPROG      zgpg30
TD           65536
SOLVENT      CDCl3
NS           1586
DS           2
SWH          17985.611 Hz
FIDRES      0.27459 Hz
RG           1.11585
RG           11585.2
DM           27.800 usec
DE           6.50 usec
DI           3.00 usec
D1           2.00000000 sec
D11          0.03000000 sec
TDO         1
===== CHANNEL f1 =====
NUC1         13C
P1           13.50 usec
PL1         -1.00 dB
SFO1        75.4752953 MHz
===== CHANNEL f2 =====
NUC2         13C
PCPD2       86.00 usec
PL2         2.00 dB
PL3         17.78 dB
SFO2        300.1312005 MHz
SI          32768
RG          1.11585
SFO         75.4677586 MHz
SSB         0
LB          0.30 Hz
GB          1.40
PC
  
```


The detailed ^{13}C NMR spectrum of compound **2e** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2e** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2e** (144–140 ppm)



The detailed ^{13}C NMR spectrum of compound **2e** (147–144 ppm)




The detailed ^{13}C NMR spectrum of compound **2e** (157–147 ppm)




¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound 2f

```


NAME      106611_07f111227_2
EXPNO    1
PROCNO   1
PROCRES  1
Time     20111221
Time     15:42
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
SOLVENT  CDCl3
NS       16
DS       4
SWH      8223.685 Hz
FIDRES   0.125482 Hz
AQ       3.984623 sec
RG       203
DM       50.800 usec
DE       6.50 usec
TE       300.2 K
D1       1.0030000 sec
TD0      1
===== CHANNEL f1 =====
NUC1     1H
P1       12.80 usec
PL1      0.00 dB
PL12     17.708750 dB
SFO1     400.2324716 MHz
SF1      32768
SF1M     400.2300150 MHz
WDW      EM
SSB      0
LB       0.30 Hz
GB       0
PC       1.00
  
```




¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound 2f




The detailed ^{13}C NMR spectrum of compound **2f** (135–100 ppm)




The detailed ^{13}C NMR spectrum of compound **2f** (140–135 ppm)




The detailed ¹³C NMR spectrum of compound **2f** (144–140 ppm)



The detailed ^{13}C NMR spectrum of compound **2f** (147–144 ppm)



The detailed ^{13}C NMR spectrum of compound **2f** (160–147 ppm)





¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound 2g


```

NAME 106111_syt111230_1
EXPNO 1
PROCNO 1
PROBHD 5 mm PABBO BBI
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 16
DS 4
SWH 8223.635 Hz
FIDRES 0.125483 Hz
AQ 3.964637 sec
RG 60.870 usec
DE 6.50 usec
TE 300.0 K
TD0 1.0000001 sec
===== CHANNEL f1 =====
NUC1 13C
P1 12.80 usec
PL1 -1.20 dB
PELLM 17.70875519 W
SFO1 400.2512788 MHz
SF 400.2300174 MHz
RG 300
WDW EM
SSB 0
GB 0
PC 1.20
  
```


8.032 7.650 7.629 7.378 7.247 7.106 7.085
 5.245 5.228 5.215 5.198 5.174 5.168 5.152 5.136 5.122 5.105 5.105 4.701 4.680 4.671 4.664 4.648 4.630 4.612 4.434 4.416 4.400 4.381 4.366 4.345 4.447 2.443 2.292 1.526 1.250 0.060 0.000




^{13}C NMR (75 M, $\text{CS}_2/\text{CDCl}_3$) spectrum of compound **2g**




The detailed ^{13}C NMR spectrum of compound **2g** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2g** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2g** (143–140 ppm)



The detailed ^{13}C NMR spectrum of compound **2g** (147–143 ppm)




The detailed ^{13}C NMR spectrum of compound **2g** (156–147 ppm)




¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound 2h

```


NAME      106L11_syt111227_1
EXPNO    1
PROCNO   1
Date_    20111227
Time     16
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zg30
TD        65536
SOLVENT  CDCl3
DS        2
SWH       8223.685 Hz
FIDRES   0.125483 Hz
AQ        3.9846387 sec
RG        655
DM        60.800 usec
DE        6.50 usec
TE        300.0 K
D1        1.00000000 sec
D10       1
===== CHANNEL f1 =====
NUC1      1H
P1        12.80 usec
PL1       0.00 dB
PL12      17.7087150 dB
SFO1      400.2324716 MHz
SI        32768
SF        400.2300161 MHz
WDW       EM
SSB       0
GB        0.30 Hz
PC        1.00
  
```




¹³C NMR (75 M, CS₂/CDCl₃) spectrum of compound 2h




The detailed ^{13}C NMR spectrum of compound **2h** (135–125 ppm)




The detailed ^{13}C NMR spectrum of compound **2h** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2h** (143–140 ppm)




The detailed ^{13}C NMR spectrum of compound **2h** (147–143 ppm)



The detailed ^{13}C NMR spectrum of compound **2h** (157–147 ppm)



¹H NMR (400 M, CS₂/CDCl₃) spectrum of compound **2i**




106112_syt120315_2

NAME 106112_syt120315_2
 KWNO 1
 PROCNO 1
 Date_ 20120315
 Time 10.30
 INSTRUM spect
 F1CD 500
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 64
 SI 32768
 SMH 8223.685 Hz
 FIDRES 0.125483 Hz
 AQ 3.9846387 sec
 RG 203
 DW 60.800 usec
 DE 19.200 usec
 TE 300.0 K
 D1 1.00000000 sec
 TDO 1

CHANNEL f1

NUC1 1H
 P1 12.80 usec
 PL1 -1.00 dB
 PL1W 17.78875549 W
 SF01 400.232716 MHz
 SF 400.232716 MHz
 SE 400.2300351 MHz
 WDW ro
 SSB 0
 LB 0
 GB 0
 PC 1.00


¹³C NMR (100 M, CS₂/CDCl₃) spectrum of compound **2i**




```

NAME 105514_wt1403C6_2
EXPNO 2
PROCNO 20140507
Time 16.40
INSTRUM av400
PROBHD 5 mm HBO av400
PULPROG zgpg30
TD 65536
SFO1 100.626158 MHz
NS 24576
DS 4
AQ 24698.456 Hz
ZD 0.366798 Hz
AQ 1.3632196 sec
RG 327.000
DE 6.50 usec
TE 300.0 K
D1 0.0300000 sec
D11 0.0300000 sec
D12 0.0300000 sec
D13 0.0300000 sec
D14 0.0300000 sec
D15 0.0300000 sec
D16 0.0300000 sec
D17 0.0300000 sec
D18 0.0300000 sec
D19 0.0300000 sec
D20 0.0300000 sec
===== CHANNEL f1 =====
NUC1 13C
P1 11.33
PL1 2.00 dB
SFO1 100.626158 MHz
===== CHANNEL f2 =====
NUC2 1H
P2 19.00
PL2 19.00 dB
SFO2 400.146005 MHz
===== WALTZ16 =====
NUC3 1H
PL3 19.00 usec
PL4 19.00 usec
PL5 19.00 usec
PL6 19.00 usec
PL7 19.00 usec
PL8 19.00 usec
PL9 19.00 usec
PL10 19.00 usec
PL11 19.00 usec
PL12 19.00 usec
PL13 19.00 usec
PL14 19.00 usec
PL15 19.00 usec
PL16 19.00 usec
SFO3 400.146005 MHz
SFO4 327.68 MHz
SF 100.626158 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0.10
PC 0.10
  
```


The detailed ^{13}C NMR spectrum of compound **2i** (135–125 ppm)





The detailed ^{13}C NMR spectrum of compound **2i** (140–135 ppm)




The detailed ^{13}C NMR spectrum of compound **2i** (143–140 ppm)




The detailed ^{13}C NMR spectrum of compound **2i** (147–143 ppm)




The detailed ^{13}C NMR spectrum of compound **2i** (172–147 ppm)




¹H NMR (400 M, CS₂/CDCl₃) spectrum of compounds **3a** and **4a**




The detailed ¹H-NMR spectrum of compounds **3a** and **4a** (5.7 -2.2 ppm)




The detailed $^1\text{H-NMR}$ spectrum of compounds **3a** and **4a** (8.7 - 7.2 ppm)




¹H NMR (400 M, CS₂/DMSO-d₆) spectrum of compounds **3i** and **4i**.




The detailed $^1\text{H-NMR}$ spectrum of compounds **3i** and **4i** (5.0 -2.2 ppm)




The detailed $^1\text{H-NMR}$ spectrum of compounds **3i** and **4i** (9.2 -6.5 ppm)




¹³C NMR (100 M, CS₂/DMSO-*d*₆) spectrum of compound **3i**




The detailed ^{13}C NMR spectrum of compound **3i** (133–125 ppm)




The detailed ^{13}C NMR spectrum of compound **3i** (143–133 ppm)




The detailed ^{13}C NMR spectrum of compound **3i** (168–143 ppm)



Voltammograms and data of compounds 2a-i, 5 and C₆₀




Cyclic voltammogram of compound 2a (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound 2a

compound 2a	E_1	E_2	E_3
CV	-1.133 V	-1.533 V	-2.004 V
DPV	-1.136 V	-1.532 V	-2.024 V




Cyclic voltammogram of compound **2b** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2b**

compound 2b	E_1	E_2	E_3
CV	-1.128 V	-1.532 V	-2.041 V
DPV	-1.128 V	-1.532 V	-2.064 V




Cyclic voltammogram of compound **2c** (scanning rate: 20 mVs^{-1})




Differential pulse voltammogram of compound **2c**

compound 2c	E_1	E_2	E_3
CV	-1.124 V	-1.528 V	-2.013 V
DPV	-1.124 V	-1.524 V	-2.020 V




Cyclic voltammogram of compound **2d** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2d**

compound 2d	E_1	E_2	E_3
CV	-1.135 V	-1.522 V	-2.008 V
DPV	-1.140 V	-1.524 V	-2.036 V




Cyclic voltammogram of compound **2e** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2e**

compound 2e	E_1	E_2	E_3
CV	-1.132 V	-1.517 V	-1.997 V
DPV	-1.132 V	-1.516 V	-2.020 V




Cyclic voltammogram of compound **2f** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2f**

compound 2f	E_1	E_2	E_3
CV	-1.140 V	-1.535 V	-2.043 V
DPV	-1.140 V	-1.536 V	-2.076 V




Cyclic voltammogram of compound **2g** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2g**

compound 2g	E_1	E_2	E_3
CV	-1.149 V	-1.545 V	-2.048 V
DPV	-1.148 V	-1.544 V	-2.072 V




Cyclic voltammogram of compound **2h** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2h**

compound 2h	E_1	E_2	E_3
CV	-1.118 V	-1.509 V	-1.994 V
DPV	-1.124 V	-1.512 V	-2.012 V




Cyclic voltammogram of compound **2i** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **2i**

compound 2i	E_1	E_2	E_3
CV	-1.122 V	-1.515 V	-1.963 V
DPV	-1.120 V	-1.512 V	-1.976 V




Cyclic voltammogram of compound **5** (scanning rate: 20 mVs⁻¹)




Differential pulse voltammogram of compound **5**

compound 5	E_1	E_2	E_3
CV	-1.120 V	-1.514 V	-2.000 V
DPV	-1.120 V	-1.516 V	-2.012 V



Cyclic voltammogram of compound C₆₀ (scanning rate: 20 mvs⁻¹)



Differential pulse voltammogram of compound C₆₀

C ₆₀	<i>E</i> ₁	<i>E</i> ₂	<i>E</i> ₃
CV	-1.076 V	-1.460 V	-1.925 V
DPV	-1.080 V	-1.464 V	-1.924 V